Fortrea Holdings (FTRE) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- $0.22
- Surprise
- —
- Score today
- 4.9/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Fortrea Holdings Q3 2026 Earnings Call Transcript — benzinga, 2026-10-29
- Fortrea Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-10-29
- Fortrea Holdings Raises FY2026 Sales Guidance from $2.620B-$2.690B to $2.665B-$2.690B vs $2.663B Est — benzinga, 2026-10-29
Where TrendMatrix's rating stands now
TrendMatrix currently rates FTRE Sell at 4.9/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate.
What argues against it
- Concentration risk — Customer: top ten customers (57.0%)
- Concentration risk — Customer: top 20 customers (69.0%)
- Target reached (-17.1% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $22.80
- Stop
- $21.20
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
FTRE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.46B
- P/E (fwd)
- 22.9
- 52-week range
- $8.55–$26.16
- Off 52-week high
- 12.9%
- RSI (14)
- 60
- Volume vs avg
- 0.58×
- Score today
- 4.9/10